Yana Najjar
Overview
Explore the profile of Yana Najjar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong C, Menchikova E, Najjar Y, Whiteside T, Jackson E
Oncoimmunology
. 2024 Dec;
14(1):2444704.
PMID: 39704041
The adenosinergic pathway converting endogenous ATP to adenosine (ADO) is a major immunosuppressive pathway in cancer. Emerging data indicate that plasma small extracellular vesicles (sEV) express CD39 and CD73 and...
2.
Wei A, Chen L, Orloff M, Ariyan C, Asgari M, Barker C, et al.
Pigment Cell Melanoma Res
. 2023 Oct;
36(6):542-556.
PMID: 37804122
Mucosal melanoma remains a rare cancer with high mortality and a paucity of therapeutic options. This is due in significant part to its low incidence leading to limited patient access...
3.
Luke J, Dadey R, Augustin R, Newman S, Singh K, Doerfler R, et al.
Res Sq
. 2023 Aug;
PMID: 37645831
Patients with tumors that do not respond to immune-checkpoint inhibition often harbor a non-T cell-inflamed tumor microenvironment, characterized by the absence of IFN-γ-associated CD8 T cell and dendritic cell activation....
4.
Wei Z, Waite K, Deng H, Najjar Y, Niranjan A, Lunsford L
Cureus
. 2022 Aug;
14(7):e26553.
PMID: 35936134
Melanoma is a complex disease with a high propensity for brain metastatic spread. Stereotactic radiosurgery (SRS) is a minimally invasive procedure to treat intracranial metastasis with a high rate of...
5.
Ascierto P, Butterfield L, Campbell K, Daniele B, Dougan M, Emens L, et al.
J Transl Med
. 2021 Jan;
19(1):13.
PMID: 33407605
Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies,...
6.
Zhang S, Liu R, Siripong N, Kirkwood J, Holtzman M, Davar D, et al.
J Am Acad Dermatol
. 2019 Jun;
83(2):587-590.
PMID: 31150702
No abstract available.
7.
Roy S, Pradhan D, Ernst W, Mercurio S, Najjar Y, Parikh R, et al.
Mod Pathol
. 2017 May;
30(8):1133-1143.
PMID: 28548125
Primary bladder adenocarcinoma is a rare and aggressive tumor with poor clinical outcomes and no standard of care therapy. Molecular biology of this tumor is unknown due to the lack...